Project Details
Description
An elevated level of ribosomal RNA (rRNA) production supports the uncontrolled growth of cancer cells and as a result they become "addicted" to abnormal levels of rRNA. Consequently, cancer cells become more sensitive to drugs that target rRNA production. This application explores the development and use of 2nd-generation inhibitors of the enzyme that synthesizes rRNA (Pol I) for the treatment of hematological and solid cancers.
Status | Finished |
---|---|
Effective start/end date | 1/01/19 → 31/12/22 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.